In 1990, the Human Genome Project began its quest to identify every gene in the human genome. Now, Spiral Genetics can sequence a human genome in three hours. LSIPR spoke to Spiral Genetics’ chief executive Adina Mangubat to find out how the company protects its IP.
Knowledge of human genes and their role in driving diseases has become increasingly important in the development of personalised medicines. Genetic sequencing has come on leaps and bounds since the international Human Genome Project (HGP) was completed in 2003—after 13 years and three billion base pairs it had succeeded, two years ahead of schedule, in identifying every gene in the human genome for study.
There are two parts of genetic analysis, explains Adina Mangubat, chief executive of Spiral Genetics, which provides software packages for genetic analysis, or next generation sequencing.
The first part of the analysis is the chemistry phase, the second is computational. In the chemistry phase of the sequencing process, instead of ‘reading’ the three billion base pairs that make up the human genome from beginning to end as was done in the HGP, which is not particularly efficient, the string of information is broken down into 100 base pair-long chunks to make the analysis more manageable.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Spiral Genetics, IP strategy, genetics, genetic screening, genome sequencing